204693-24-3 Usage
Molecular structure
The compound has a complex molecular structure consisting of a piperazine ring, a lysine residue with a protective group, a tyrosine residue with a protective group, and a pyridine ring.
Protective groups
The lysine residue has a 1,1-dimethylethoxycarbonyl protective group, and the tyrosine residue has a 9-fluorenylmethoxycarbonyl protective group.
Halogen atoms
The compound contains bromine atoms (3,5-dibromo) in the tyrosine residue, which may have specific chemical properties.
Potential applications
The compound may have potential applications in the field of pharmacology or medicinal chemistry.
Further research
The specific biological or chemical activities of the compound would need to be determined through additional research and testing.
Check Digit Verification of cas no
The CAS Registry Mumber 204693-24-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,4,6,9 and 3 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 204693-24:
(8*2)+(7*0)+(6*4)+(5*6)+(4*9)+(3*3)+(2*2)+(1*4)=123
123 % 10 = 3
So 204693-24-3 is a valid CAS Registry Number.
204693-24-3Relevant academic research and scientific papers
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N 2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl) -1-piperidinyl]carbonyl]-D-tyrosyl]-L-ly
Rudolf, Klaus,Eberlein, Wolfgang,Engel, Wolfhard,Pieper, Helmut,Entzeroth, Michael,Hallermayer, Gerhard,Doods, Henri
, p. 5921 - 5931 (2007/10/03)
Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel
